US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Braveheart Bio

21.41

+1.215.99%

Volume:669.40K

Turnover:14.34M

Market Cap:1.93B

PE:-1.46

High:22.36

Open:19.90

Low:19.88

Close:20.20

52wk High:32.00

52wk Low:19.88

Shares:90.04M

Float Shares:25.83M

Volume Ratio:1.14

T/O Rate:2.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-14.6845

EPS(LYR):-17.2003

ROE:--

ROA:--

PB:-20.10

PE(LYR):-1.24

Loading ...

Overview Company News Filings

OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta

Insiders Double Down as Major Investor Piles Into Braveheart Bio

Press Release: Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Top Midday Gainers

MT Newswires Live

Braveheart Bio Shares Rise After Market Debut

MT Newswires Live

Braveheart Bio opens at $30.20, IPO priced at $18 per share

Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO

U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International

Braveheart Bio indicated to open at $30, IPO priced at $18

Braveheart Bio Poised to Surge in New York Debut After Upsized $383 Million IPO

Braveheart Bio 21.25M share IPO priced at $18.00

Braveheart Bio Prices Upsized Initial Public Offering on Nasdaq at $18 per Share

MT Newswires Live

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

THOMSON REUTERS

Braveheart Bio - Prices Upsized IPO of 21,250,000 Shares at $18 Per Share

THOMSON REUTERS

Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BRVE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":21.41,"timestamp":1790884800000,"preClose":20.2,"halted":0,"volume":669404,"delay":0,"changeRate":0.05990099009900995,"floatShares":25831738,"shares":90039000,"eps":-14.684527,"marketStatus":"Pre-Mkt","change":1.21,"latestTime":"10-02 04:29:18 EDT","open":19.9,"high":22.355,"low":19.88,"amount":14339530.011956,"amplitude":0.122525,"askPrice":26.59,"askSize":100,"bidPrice":16.47,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.684527,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":21.41,"postHourTrading":{"tag":"盘后","latestPrice":21.83,"preClose":21.41,"latestTime":"19:40 EDT","volume":6714,"amount":143839.28,"timestamp":1790898027302,"change":0.42,"changeRate":0.019617,"amplitude":0.019617},"volumeRatio":1.1365428343228008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":25831738,"roa":"--","roe":"--","lyrEps":-17.200311,"volumeRatio":1.1365428343228008,"shares":90039000,"dividePrice":0,"high":22.355,"amplitude":0.122525,"preClose":20.2,"low":19.88,"week52Low":19.88,"pbRate":"-20.10","week52High":32,"institutionHeld":0,"latestPrice":21.41,"eps":-14.684527,"divideRate":0,"volume":669404,"delay":0,"ttmEps":-14.684527,"open":19.9,"prevYearClose":18,"prevWeekClose":20.62,"prevMonthClose":20.2,"prevQuarterClose":20.2,"fiveDayClose":23.37,"twentyDayClose":26.95,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-09-30","current":-1.457997,"percent":0.871795,"low":-23.993466,"twenty":-22.06759,"median":-20.842324,"eighty":-16.773912,"high":-12.297967,"avg":-19.651355,"sd":2.991281,"marketCap":1464634862},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250},{"date":"2026-09-04","current":-21.010278,"twenty":-22.169963,"median":-21.930028,"eighty":-20.827928,"marketCap":1685717659},{"date":"2026-09-11","current":-18.437402,"twenty":-22.185958,"median":-21.618113,"eighty":-20.469626,"marketCap":1748603206},{"date":"2026-09-18","current":-18.748639,"twenty":-22.118777,"median":-21.390175,"eighty":-18.607905,"marketCap":1778120911},{"date":"2026-09-25","current":-16.155238,"twenty":-22.096383,"median":-21.010278,"eighty":-18.113986,"marketCap":1532162790},{"date":"2026-09-30","current":-15.443219,"twenty":-22.06759,"median":-20.842324,"eighty":-16.773912,"marketCap":1464634862}],"updateTime":1790910833189},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRVE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658494615","title":"OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658494615","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658494615?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:28","pubTimestamp":1786483716,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors acquires 1.940.000 Braveheart Bio common shares worth $ 34,92 jutaBraveheart Bio melaporkan OrbiMed Advisors meningkatkan kepemilikan tidak langsung menjadi 11.901.826 saham biasa.Pos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8hq9sF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622953","title":"Insiders Double Down as Major Investor Piles Into Braveheart Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657622953?lang=en_us&edition=fundamental","pubTime":"2026-08-08 10:02","pubTimestamp":1786154530,"startTime":"0","endTime":"0","summary":"New insider activity at Braveheart Bio, Inc. ( ($BRVE) ) has taken place on August 7, 2026. Braveheart Bio, Inc. has seen a wave of insider and maj...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-major-investor-piles-into-braveheart-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-major-investor-piles-into-braveheart-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657268036","title":"Press Release: Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657268036","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657268036?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","LU0154245756.USD","BK4588","IPOS","BRVE","BK4567","LU0289961442.SGD","LU0472753341.HKD","LU0057025933.USD","LU0069063385.USD","LU0289739343.SGD","HCM","LU0203345920.USD","LU0203347892.USD","LU2463526074.USD","BK4007","BK4533","MADE","CMI","BK4149","LU0154245673.USD","BK4585","LU0511384066.AUD","LU0124676726.USD","IE000M9KFDE8.USD","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651922","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651922?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:58","pubTimestamp":1786039111,"startTime":"0","endTime":"0","summary":"ClearOne's  majority stockholder, First Finance, has provided written consent approving the issuance of 12.5 million new common shares to Vivani Medical, a condition required to close its planned merger with Vivani unit Cortigen, the company said in a regulatory filing.Shares of ClearOne soared 157% amid a surge in intraday trading volume to over 59.7 million from a daily average of about 3.23 million.Braveheart Bio's  unveiled an upsized initial public offering of 21.25 million common shares late Wednesday.Shares surged 66% as intraday trading volume jumped to over 1.74 million.Motorola Solutions  delivered a better-than-expected Q2, driven by continued outperformance from Silvus Technologies in defense markets and a surprise return to growth in its Land Mobile Radio business, Morgan Stanley said in a Thursday research note.Shares jumped 8.2%, with intraday trading volume rising to more than 1.06 million from the stock's daily average of about 1.13 million.Price: 9.37, Change: +5.61, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2272731865.HKD","LU0234570918.USD","LU2272731600.USD","BK4534","LU1720051108.HKD","LU0320765646.SGD","LU0795875086.SGD","LU2322448791.USD","LU1992135399.USD","IAI","LU2264538146.SGD","LU1989772840.SGD","BRVE","LU0354030438.USD","LU0314104364.USD","LU2271345857.HKD","MSI","LU0106261372.USD","LU2125909916.SGD","LU1992135472.HKD","LU0107464264.USD","BK7031","LU2065171402.SGD","LU2106854487.HKD","KBWB","LU2028103732.USD","LU0557290698.USD","LU2089284900.SGD","BK4127","LU1548497426.USD","LU1244550221.USD","LU1732800096.USD","LU2473716301.USD","LU2487616109.SGD","LU1923622291.USD","LU1791710400.SGD","LU0882574139.USD","LU2111349929.HKD","LU1162221912.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","BK4588","LU1074936037.SGD","BK4504","LU0210528500.USD","MSI.AU","LU2125909759.SGD","LU0823417737.USD","CLRO","EYES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659460","title":"Braveheart Bio Shares Rise After Market Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659460","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657659460?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:25","pubTimestamp":1786037119,"startTime":"0","endTime":"0","summary":"Braveheart Bio  shares rose 69.8% in Thursday trading after the company announced an upsized initial public offering of 21.25 million common shares late Wednesday.The stock opened for trading Thursday at $30.20, compared with its public offering price of $18 per share.The offering is expected to close Friday, subject to customary closing conditions.Price: 30.53, Change: +12.53, Percent Change: +69.58","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656750","title":"Braveheart Bio opens at $30.20, IPO priced at $18 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656750?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:55","pubTimestamp":1786035323,"startTime":"0","endTime":"0","summary":"Braveheart Bio (BRVE) – a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and othe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-opens-at-30-20-ipo-priced-at-18-per-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-opens-at-30-20-ipo-priced-at-18-per-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","IPOS","REDS","FRHC","BRVE","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150536472","title":"Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1150536472","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150536472?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:52","pubTimestamp":1786035174,"startTime":"0","endTime":"0","summary":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657703655","title":"U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International","url":"https://stock-news.laohu8.com/highlight/detail?id=2657703655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657703655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:22","pubTimestamp":1786033341,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln InternationalAugust 6 (Reuters)-Wall Street's benchmark S&P 500 struggled for direction in choppy trading on Thursday as inv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL6N44314S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SITM","USFD","CHYM","CELH","LNG","PRMB","SRE","IOVA","FLNC","APP","HWM","MAC","PZZA","VTRS","PH","UWMC","BLLN","SNDK","RXO","RL","U","SMR","EPAM","OSCR","VCTR","BRVE","MRNA","FISV","PTON","LEU","RDVT","RCBC","SPCX","KDP","FRT","KVUE","WDC","MTSI","INSM","FIG","GBFH","CEG","DDOG","HONA","PAYC","LCLN","FOUR","ELF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657555236","title":"Braveheart Bio indicated to open at $30, IPO priced at $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2657555236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657555236?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:50","pubTimestamp":1786031427,"startTime":"0","endTime":"0","summary":"Braveheart Bio (BRVE) priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced ab...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-indicated-to-open-at-30-ipo-priced-at-18-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-indicated-to-open-at-30-ipo-priced-at-18-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KCE","BK4127","IPOS","FRHC","REDS","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865868","title":"Braveheart Bio Poised to Surge in New York Debut After Upsized $383 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865868","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657865868?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:49","pubTimestamp":1786027798,"startTime":"0","endTime":"0","summary":"BUZZ-Braveheart Bio poised to surge in New York debut after upsized $383 million IPO** Drug developer Braveheart BioBRVE.Oon track to open above offer price in Nasdaq debut after upsized $382.5 million U.S. IPO** Stock recently indicated to open at $25 apiece vs $18 offer price** San Francisco, California-based BRVE sold ~21.3 million shares inupsized IPOat $18 apiece** BRVE, which is developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases, had initially marketed 18.75 million shares priced between $15 and $17** Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor acted as joint book-running managers for offering","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL6N44311L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443978.SGD","BK4533","LU2471134523.USD","LU0345770308.USD","LU2750360641.GBP","LU1894683264.USD","LU2237443549.SGD","LU2237438978.USD","IE0034235188.USD","IE0004086264.USD","LU1868837300.USD","LU1668664300.SGD","BK4127","LU2471134879.HKD","LU0868494708.USD","LU0868494617.USD","IE0002270589.USD","LU0345770993.USD","GSX","LU0096364046.USD","LU1868836591.USD","SF","LU2237443465.HKD","LU1804176565.USD","LU1868836914.USD","BK4585","LU2471134952.CNY","LU2237443895.HKD","LU2265009873.SGD","IE00BFXG1179.USD","LU2237443622.USD","LU0251131958.USD","IE0004091025.USD","LU0048573561.USD","IE00BSNM7G36.USD","LU2471134796.USD","BRVE","BK4504","BK4552","BK4588","IE00B19Z3B42.SGD","LU0251142724.SGD","LU1791807156.HKD","BK4550","LU0106831901.USD","LU2237443382.USD","LU0061475181.USD","LU0742534661.SGD","LU0942090050.USD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682108","title":"Braveheart Bio 21.25M share IPO priced at $18.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682108?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:17","pubTimestamp":1786011473,"startTime":"0","endTime":"0","summary":"The deal size was increased to 21.25M shares of common stock from 18.75M shares of common stock and priced above the $15.00-$17.00 range. Goldman S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-21-25m-share-ipo-priced-at-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-21-25m-share-ipo-priced-at-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSX","LU2237443895.HKD","LU0251131958.USD","LU0048573561.USD","FRHC","LU0106831901.USD","BK4127","LU2471134796.USD","LU2237443382.USD","IPOS","BK4585","LU0251142724.SGD","LU1868836757.USD","BRVE","LU0742534661.SGD","IE0004086264.USD","LU0345770308.USD","LU2471134523.USD","LU0345770993.USD","LU2471134952.CNY","LU2750360641.GBP","LU1868836591.USD","LU1894683264.USD","LU0061475181.USD","LU2237443978.SGD","IE00BFXG1179.USD","IE0034235188.USD","IE00B19Z3581.USD","LU0868494708.USD","LU2237443622.USD","BK4516","LU1804176565.USD","LU2237443465.HKD","LU1791807156.HKD","BK4550","IE0002270589.USD","IE00BSNM7G36.USD","IE0004091025.USD","BK4588","BK4552","LU0868494617.USD","LU0942090050.USD","LU2471134879.HKD","LU0096364046.USD","KCE","BK4504","LU1668664300.SGD","LU1868836914.USD","LU1868837300.USD","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681246","title":"Braveheart Bio Prices Upsized Initial Public Offering on Nasdaq at $18 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657681246?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:42","pubTimestamp":1786009378,"startTime":"0","endTime":"0","summary":"Braveheart Bio  priced its upsized initial public offering of approximately 21.3 million shares at $18 per share, the company said late Wednesday.All shares in the offering are being sold by Braveheart Bio.The shares are expected to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE. Braveheart Bio said the offering is expected to close on Friday.The company said it also granted the underwriters a 30-day option to purchase up to an additional 3.2 million shares at the IPO price.Braveheart Bio expects to generate approximately $382.5 million in gross proceeds from the offering.Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are acting as joint book-running managers.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE","NQmain","IPOS","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657503762","title":"Braveheart Bio Announces Pricing of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657503762?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:33","pubTimestamp":1785983613,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA3QB2GK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657037645","title":"Braveheart Bio - Prices Upsized IPO of 21,250,000 Shares at $18 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657037645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657037645?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:33","pubTimestamp":1785983613,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA3QB2GK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109016136","title":"Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1109016136","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109016136?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:45","pubTimestamp":1784123139,"startTime":"0","endTime":"0","summary":"Clinical-stage biopharmaceutical firm Braveheart Bio Inc., which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0234570918.USD","BK4532","BRVE","BK4585","IE00B19Z9Z06.USD","LU0109394709.USD","IE00B894F039.SGD","LU0889565916.HKD","BMED","BK4533","BK4139","BIIB","BK4588","IE00B19Z9P08.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}